GlassScriptPhysician profile
Namrata Paul
NPI 1285086637
$649.80
in general payments reported to CMS, 2019-2025
11 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.36 · 2022: $147 · 2023: $178 · 2024: $206 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $337.63 | 2022-2025 | Minimed 780g, Minimed 770g |
| Lilly USA, LLC | $82.51 | 2022-2024 | Mounjaro |
| Amneal Pharmaceuticals LLC | $53.85 | 2024-2025 | Unithroid |
| Novo Nordisk INC | $33.63 | 2023-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $33.25 | 2024-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $31.90 | 2023 | Strensiq |
| Xeris Pharmaceuticals, INC. | $16.00 | 2022 | |
| Insulet Corporation | $15.91 | 2024 | Omnipod |
| Tandem Diabetes Care, INC. | $15.36 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.92 | 2022 | |
| Amgen INC. | $14.84 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namrata Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.